Formulation of rifampicin–cyclodextrin complexes for lung nebulization
| Autor: | William Couet, Julien Brillault, Frederic Tewes, Jean-Christophe Olivier |
|---|---|
| Přispěvatelé: | Modélisations pharmacocinétiques-pharmacodynamiques pour un meilleur usage des anti-infectieux, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Poitiers, Université de Poitiers - Faculté de Médecine et de Pharmacie, Université de Poitiers, Tewes, Frederic, Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM) |
| Rok vydání: | 2008 |
| Předmět: |
Acinetobacter baumannii
MESH: Hydrogen-Ion Concentration Chemistry Pharmaceutical Pharmaceutical Science 02 engineering and technology Pharmacology rifampicin 030226 pharmacology & pharmacy chemistry.chemical_compound 0302 clinical medicine Drug Stability [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases MESH: Respiratory Mucosa polycyclic compounds Solubility Aerosolization Antibacterial agent MESH: Technology Pharmaceutical chemistry.chemical_classification Drug Carriers MESH: Kinetics Cyclodextrin Chemistry MESH: Models Chemical beta-Cyclodextrins MESH: Administration Inhalation Hydrogen-Ion Concentration [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences 021001 nanoscience & nanotechnology 2-Hydroxypropyl-beta-cyclodextrin Anti-Bacterial Agents 3. Good health [SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences MESH: Drug Carriers MESH: Permeability Rifampin 0210 nano-technology Drug carrier medicine.drug MESH: beta-Cyclodextrins Calu-3 Drug Compounding Respiratory Mucosa Cell Line lung Inclusion compound MESH: Nebulizers and Vaporizers MESH: Chemistry Pharmaceutical 03 medical and health sciences Pharmacokinetics MESH: Drug Stability MESH: Anti-Bacterial Agents Administration Inhalation medicine Humans Technology Pharmaceutical MESH: Particle Size Particle Size MESH: Humans Chromatography MESH: Acinetobacter baumannii Nebulizers and Vaporizers bacterial infections and mycoses MESH: Rifampin MESH: Cell Line MESH: Solubility Kinetics Models Chemical cyclodextrin MESH: Drug Compounding permeability Rifampicin |
| Zdroj: | Journal of Controlled Release Journal of Controlled Release, Elsevier, 2008, 129, pp.93-99. ⟨10.1016/j.jconrel.2008.04.007⟩ Journal of Controlled Release, Elsevier, 2008, 129 (2), pp.93-9. ⟨10.1016/j.jconrel.2008.04.007⟩ |
| ISSN: | 0168-3659 |
| Popis: | International audience; Lung administration of antibiotics by nebulization is promising for improving treatment efficiency for pulmonary infections, as it increases drug concentration at sites of infection while minimizing systemic side effects. For poorly soluble molecules like rifampicin, cyclodextrins (CD) may improve lung delivery by permitting higher dosing. For this purpose, we investigated rifampicin-CD complexes in terms of rifampicin apparent solubility enhancement, effect on in vitro permeability on Calu-3 broncho-alveolar cells, effect on in vitro antibacterial activity against Acinetobacter baumannii and nebulization characteristics measured by NGI cascade impactor. Complexation efficiency between rifampicin and methylated beta-cyclodextrin (RAMEB) or hydroxypropyl-beta-cyclodextrin (HPbetaCD) was pH-dependent, involving the piperazin group. Rifampicin phase solubility diagrams constructed at pH 9 showed an A(L)-type curve for RAMEB and a B(S)-type for HPbetaCD. Stability constants calculated for a 1:1 molar ratio of CD/rifampicin were 73.4 +/- 8.2 M(-1) for RAMEB and 68.5 +/- 5.2 M(-1) for HPbetaCD. Complexes with RAMEB or HPbetaCD increased 22 times and 7.6 times respectively the apparent solubility of rifampicin and were found to be satisfactorily stable for 2 days when diluted in a solution at physiological pH. The nebulization of the complex solution created droplets in size range compatible with pulmonary deposition. Furthermore, the presence of HPbetaCD decreased the MMAD of the aerosolized droplets. Activity of RAMEB and HPbetaCD complexes measured by the total rifampicin MIC against A. baumannii was similar or lower to free rifampicin MIC respectively. Complexation did not alter the rifampicin permeability in the timescale of 1h as evaluated with a Calu-3 epithelial cell model, but acted as a reservoir for rifampicin. In conclusion, this work reports that CDs can be used as vectors for pulmonary nebulization to increase the amount of active rifampicin and optimize its lung pharmacokinetic profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect